Drugs / Levonorgestrel/Ethinyl Estradiol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03547024 | Jun → Aug 2018 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levonorgestrel/Ethinyl Estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547024 ↗ |
| Route | Oral | “Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.” NCT03547024 ↗ |